Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:

GSK Puerto Rico Plant Under Investigation By FDA; Received Warning In 2002

  • News

Executive Summary

GlaxoSmithKline does not anticipate any immediate supply disruptions from an FDA investigation of its Cidra, Puerto Rico production facility

You may also be interested in...



Schering GMPs Linger: Whistleblower Suit Filed, Consent Decree Extended

Schering-Plough has been named in a False Claims Act suit alleging the company (and two dozen other manufacturers) knowingly sold adulterated products to the federal government

Paxil OS GMP Concerns Resolved By Year-End, GSK Says After Warning Letter

GlaxoSmithKline expects to resolve GMP issues related to production of Paxil oral suspension at its Certenejas Cidra, Puerto Rico facility by the end of the month, the company said

GSK Manufacturing Consolidation Has Helped GMP Compliance, Firm Says

GlaxoSmithKline's manufacturing streamlining has helped the company avoid trouble during the recent round of FDA good manufacturing practices enforcement, CEO J.P. Garnier told investors Oct. 23

Table

View full table

Tags:
UsernamePublicRestriction

Register

ID007083

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By